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The five year survival of juvenile systemic sclerosis
(jSSc) is around 95%. Patients, who died in the two ret-
rospective cohorts, died mostly in the first 24 months of
disease course. Autologous bone marrow transplantation
(ABMT) seems to be a promising therapeutic approach
for adult patients ( ASTIS (EU) and SCOT (USA)Trial)
with severe disease course. Around 8 patients with jSSc
are transplanted according the EBMT registry. Currently
no consent based inclusion or exclusion criteria for
ABMT in jSSc exists.
Aim of the survey was to get a feeling from paediatric
rheumatologists, when they would apply autologous
bone marrow transplantation as a treatment option.
Paediatric Rheumatologist - members of the PRES
Juvenile Scleroderma Working Group and participants
of the Paediatric Rheumatology E-mail Board were
asked via Internet to fill out the survey
22 centres responded, all of them were academic cen-
tres. BMT would be considered for 14 of the 22 collea-
gues after nonresponse to cyclophosphamide, 10 of 22
after non response to two DMARDs and 12 of 22 after
nonresponse to Rituximab. 19 of 22 would consider
transplantation if the CHAQ score ≤ 2 , 20 of 22 if the
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transplantation if the modified Rodnan skin score is
more than 30 and 15 of 22 if the DLCO is less than
50%, 18 of 22 if the WHO functional class is 3, 14 of 22
if the FVC less than 60%, 15 of 22 if the pulmonary
arterial pressure more than 40 mm/hg and 11 of 22 if
left ventricular ejection fraction is less than 40%.
This survey represents an impression, when pediatric
rheumatologist would consider ABMT. It is a starting
point for a possible evolving ABMT program for this
orphan disease
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